Related Experiment Video

Updated: Jul 8, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells

Chien-Chih Ou1, Shih-Chung Hsu, Yin-Hui Hsieh

  • 1Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan 114, Republic of China.

Carcinogenesis
|January 5, 2008
PubMed

Insights

Interferon-gamma (IFN-gamma) triggers retinoid-inducible gene 1 (RIG1) to suppress HER2 oncoprotein in prostate cancer. RIG1 downregulates key signaling pathways, offering potential therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Interferon-gamma (IFN-gamma) is recognized for its ability to reduce HER2 oncoprotein levels in prostate cancer.
  • The precise molecular mechanisms underlying IFN-gamma's effects on HER2 signaling require further elucidation.

Purpose of the Study:

  • To investigate the role of retinoid-inducible gene 1 (RIG1) in mediating the effects of IFN-gamma on HER2 oncoprotein.
  • To identify the downstream signaling pathways affected by RIG1-mediated HER2 downregulation.

Main Methods:

  • Utilized prostate cancer cell models to study the interaction between IFN-gamma, RIG1, and HER2.
  • Analyzed the phosphorylation status of key signaling molecules including HER2, PI3K/Akt, and mTOR.
  • Assessed the expression levels of vascular endothelial growth factor (VEGF) in response to RIG1 activity.

Main Results:

  • Demonstrated that IFN-gamma induces RIG1, which functions as a transrepressor of HER2 oncoprotein (p185).
  • Showed that RIG1 downregulates the activated forms of p185, PI3K/Akt, and mTOR.
  • Confirmed that RIG1 also downregulates VEGF expression via the HER2 and Akt/mTOR pathways, and that heregulin (HRG) can restore p185 and Akt activity.

Conclusions:

  • RIG1 plays a critical role in IFN-gamma-mediated suppression of HER2 and its downstream signaling pathways (PI3K/Akt/mTOR/VEGF) in prostate cancer.
  • These findings suggest RIG1 as a potential therapeutic target for enhancing IFN-gamma efficacy in prostate cancer treatment.

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...